Sentences with phrase «at the approval ratings»

And it's true that the change in voting intentions has been less dramatic - but nonetheless, as my colleague Roger Mortimore has pointed out, at this stage of a parliament it can be just as useful to look at approval ratings as voting intention.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

On Friday, Trump's approval rating stood at 42.8 % in the average — the first time it's been at that level in more than 11 months.

The ongoing scandals involving President Donald Trump could put an end to his presidency at a time when his approval ratings are at an all - time low, a political analyst told CNBC on Monday.

President Donald Trump's approval rating is at its highest point in the RealClearPolitics average since May 8, 2017.

Putin's approval rating stands at an even more astronomical 88 %.

Britain's housing market continued to lose momentum data showed too, with mortgage approvals at their weakest in nearly three years following the Bank of England's first interest rate hike in a decade.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

With approval rating in the low teens just five months into her second term, Rousseff's also struggling to win back the public trust amid Brazil's biggest corruption investigation, an inquiry into a massive kickback scheme at state - run oil company Petrobras.

According to FiveThirtyEight, the dismal approval rating makes this plan the least popular tax bill in at least 30 years — even less so than two in the 1990s that increased some taxes.

Sure, his approval ratings are at a record low and his influence on Capitol Hill is a mixed bag at best.

And while Xi is riding high after consolidating power at a twice - a-decade Communist Party Congress last month, Trump comes to China saddled with low public approval ratings and dogged by investigations into Russian links to his election campaign.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

And, many times, short - term business loans may come with faster approval rates than more traditional long - term financing at the bank — which helps when time is of the essence.

Small business loan approval rates at big banks ($ 10 billion + in assets) rose to 20 % in June from 19.6 % in May, while approval rates at small banks slipped to 51.4 % from to 51.6 % last month.

Sanders maintained his spot at the top of the list from November, with an 80 percent approval rating.

Democrats» ratings of Trump have held steady at just 8 % approval among Democratic men and 7 % among Democratic women.

Our new report uses more than 250,000 interviews with registered voters to provide insights at the national, state, and aggregated district level on President Trump's approval, key senator approval & re-elect ratings, generic ballot, and top issues for voters.

In June, loan approval rates at credit unions improved slightly to 43.7 % from 43.6 % in May, while approval rates by alternative lenders slipped for the fifth consecutive month to 63.2 % in June, from 63.3 % in May «Entrepreneurs are getting funding from banks at attractive interest rates.

APRs at Upgrade are competitive, with rates comparable to those at LendingClub, and funding is quick — most applicants receive money within one to four business days after approval.

She faces significant pressure from a newly elected Hollande, a political leader in Monti whose approval ratings are plummeting at home and needs to show some form of success on the European state, and a leader in Rajoy whose management of his country's banking crisis has been widely criticized.

Heather Long writes: «[T] he GOP faces a conundrum: While Americans feel good about the economy, Trump's approval ratings remain at anemic levels.

This widening in the gap between fixed and variable housing rates is likely to have contributed to the pick - up in the proportion of borrowers choosing to take out fixed - rate housing loans: in November 2004, the latest available data, 11 per cent of new owner - occupier housing loan approvals were at fixed rates, up from 7 per cent three months earlier and the highest share since the beginning of 2004, which followed a period of monetary policy tightening (Graph 45).

Look at different offers, rates, transfer fees, and criteria for approval.

While the proposal at the 2015 AGM received 67.4 % shareholder approval, the 2016 AGM looks to continue the Company's preferred approach of sticking to old habits that die hard rather than addressing underlying shareholder concerns, as it has again chosen not to disclose the maximum discount rate.

Competitive rates calculated monthly at the time of loan approval.

While meeting these requirements won't guarantee approval, you can check your rate at Peerform to see if you qualify.

There's a reason why the president's approval ratings are ticking up — because he's productive at his job and this is a distraction.»

Assuming that approvals remain at their new lower level, housing credit growth would be expected to slow from a three - month - annualised rate of 25 per cent to a still rapid rate of around 18 per cent by mid 2005 (Graph C4).

The increases in new loan approvals recorded through most of 1997 did not lead to an increased rate of growth in loans outstanding, because principal repayments were increasing at the same time.

Finally, rather than falling, if the value of loan approvals was to grow by 2 per cent per month from the November 2003 level until the end of 2004, housing credit growth would be expected to remain at around its current rate of close to 25 per cent.

Again, empirical work suggests that, at current levels of approvals and credit growth, a once - only 10 per cent decline in approvals would reduce the monthly rate of credit growth by around 0.3 of a percentage point after about three months (Graph C3).

Come and experience the low interest rate of 3 %, urgent response in loan approval and we don't look at your credit score.

According to the poll, the president's approval rating among Protestants and other Christians was 43 percent, it stood at 50 percent for Catholics, 61 percent among Jews, 63 percent for Atheists, Agnostics and those with no religion, and 64 percent for those from other non-Christian religions.

At any rate, Shakespeare's recusancy is sufficiently well established to survive the approval of First Things.

A new study shows America's current approval rating of Congress stands at a dumbfounding 5 %) but Cox is hoping others will join his rogue mission to keep our national beautiful.

Meanwhile, an ongoing World magazine survey of more than 100 evangelical leaders has consistently found Rubio at the top over the past eight months, including a 49 percent approval rate in February.

In September 2008, in polls performed by various agencies, George Bush's approval rating ranged from 19 % — the lowest ever to 34 % and his disapproval rating stood at 69 %.

Over at Fox they are still concerned about the approval rating of the country's worst president.

This weekend could be a turning point is Wenger's approval ratings this season when we travel to face the struggling Manchester United of Jose Mourinho, but before we head to Old Trafford I think it is worth taking a look at the Premier League salary numbers printed by the Evening Standard today.

Overall, Trump's approval rating stands at 44 %, a «record low for a newly inaugurated commander - in - chief.»

His approval ratings are now [at their lowest since June 2000], and it's reached the point where people are willing to consider alternatives.

Any development proposals that already have preliminary approval will be charged at the previous rate, he said.

Voter approval of the plan would allow the district to keep its tax rate at the present level after a bond debt is paid off next year.

«Because awards are only given to hotels that receive a high rating from both our team of experts and family travelers who have stayed at the property, the Family Vacation Critic Favorite Hotels designation offers parents a credible stamp of approval to use when searching for the perfect hotel for their family.»

In New Lenox, the Public Library District is seeking voter approval of a 13 - cent increase in its tax rate to restore hours of service at the library that were cut after a proposed 15 - cent tax rate increase was rejected in November.

Michelle Obama is probably the most popular first lady in recent memory, with approval ratings embarrassingly higher than her husband's, at least in 2012.

Gordon Brown has continued his political slide into the parliamentary recess, with the latest opinion poll putting his personal approval rating at an all - time low.

But Senate Republicans have been more than eager to join themselves at the hip with Cuomo, who has a stead 70 percent approval rating thanks in part to his legislative successes.